Anti-liver FABP antibody [EPR20147-17] - BSA and Azide free (Capture)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Liver fatty acid binding protein (liver FABP) also known as L-FABP or FABP1 is a small protein with a mass of approximately 14 kilodaltons. It functions mainly in the liver where it binds free fatty acids and other lipophilic substances facilitating their transport within cells. This protein is highly expressed in hepatocytes and also found in the small intestine and kidneys. Its role in binding fatty acids positions it as an important mediator in lipid metabolism making it of interest in a variety of metabolic studies.

Biological function summary

Liver FABP is essential for maintaining lipid homeostasis within cells. It is not part of a larger complex but acts by itself to regulate the intracellular concentration of lipids and protect cells from lipotoxicity. By sequestering fatty acids it prevents these molecules from disrupting cellular membranes or signaling pathways. Liver FABP also participates in the uptake transport and metabolic conversion of fatty acids and their metabolites influencing energy homeostasis and other vital processes.

Pathways

Liver FABP plays a significant role in the fatty acid metabolism and peroxisome proliferator-activated receptor (PPAR) signaling pathways. It acts by modulating the availability of lipid ligands necessary for PPAR activation linking it functionally to these nuclear receptors that control gene expression involved in lipid and glucose metabolism. Liver FABP's association with proteins like FABP2 and FABP4 within these pathways provides insight into its broader metabolic network highlighting its interactions in fatty acid transport and metabolism.

Associated diseases and disorders

Liver FABP shows a strong connection to metabolic conditions particularly non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Its dysregulation is often observed in these disorders which include altered lipid profiles and insulin resistance. Liver FABP is also linked to certain forms of cancer with aberrant expression levels found in some tumor types. The interactions of liver FABP with proteins such as FABP5 in these diseases suggest a potential role in the pathogenesis of metabolic disorders and tumor development making it a candidate for further research and therapeutic targeting.